Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.

Early molecular response has been associated with clinical outcome in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The BCR-ABL1 transcript rate decline from baseline to 3 months has been demonstrated to be more predictive than a single BCR-ABL1 level at 3 months (...

Descripción completa

Detalles Bibliográficos

Publicado en:	Annals of Hematology Vol. 98; no. 5; pp. 1159 - 1169
Autores principales:	Dulucq, Stephanie, Etienne, Gabriel, Morisset, Stephane, Klein, Emilie, Chollet, Claudine, Robbesyn, Fanny, Turcq, Beatrice, Tigaud, Isabelle, Hayette, Sandrine, Nicolini, Franck E., Mahon, François-Xavier
Formato:	research tables/charts Journal Article
Publicado:	Springer Nature May2019
Acceso en línea:	Ver este registro en EBSCOhost